For the record, I am posting the news releases I found at the new website.
SCANDIA, MN -- Nov. 01, 2000 -- Immulabs Corporation (OTCBB:IMLB) (www.Immulabs.com) announced today it has obtained exclusive rights to acquire Quest Research Group, Inc. of Massachusetts, headed by Dr. Bertram Eichel, a published and respected scientist in the field of biochemistry.
In addition, Immulabs has obtained the rights to acquire two technologies developed by Dr. Eichel, the 'Neutrophil Toxicity Assay', (NTAssayTM) and the 'Sensi FilterTM'. Both technologies are patent-pending as of Sept. 1st, 2000, and both potentially offer exciting breakthrough benefits for mankind as well as significant revenue potential for the Company.
New Bioassay-Filter Technology Aimed at Making Smoking Less Hazardous.
It is well known that cigarette smoke contains over 4,000 compounds, some of which are extremely toxic. It is also well known that tens of thousands of smokers die every year as a direct consequence of inhaling these deadly substances. Immulabs has obtained the rights to acquire a new filter technology that is able to selectively remove some of the most toxic gases from cigarette smoke, thereby potentially making smoking less hazardous, as described below.
Human white blood cells, specifically neutrophils, are essential to the immune system and they form an important part of the body's main defense against foreign organisms and the toxins those organisms produce. Dr. Eichel has developed a technique, called NTAssayTM, that allows scientists to harvest viable and functional neutrophils directly from the human oral cavity, without invasion into the blood stream. Using NTAssayTM, Dr. Eichel discovered that the smoke of just one cigarette contains more than enough toxic gaseous material to severely and adversely affect all exposed human oral neutrophils in-vivo (inside the body). Every conventional cigarette tested, filtered or non-filtered, regardless of brand, produced similar devastating results. To our knowledge, this discovery was and remains the first scientific evidence of its kind, and could have far-reaching implications for the global tobacco industry.
After extensive testing, Dr. Eichel developed a method of selectively filtering these harmful gasses, such as Acrolein and Hydrogen Cyanide, from tobacco smoke using a prototype for an improved filter. This filter is called the Sensi FilterTM. During controlled experiments, human oral cavity white cells (neutrophils) remained healthy and viable after exposure to this new filtered tobacco smoke. Sensi FilterTM technology reduced and/or eliminated certain harmful gases from the smoke stream to such an extent that the white blood cell impairment ceased, and viable functioning cells continued to be apparent.
Importantly, use of the 'Sensi FilterTM' does not impair the smoker's enjoyment, as the taste and aroma of the smoke is not adversely affected. In fact, most test subjects reported that the 'Sensi FilterTM' smoke tasted better, probably due to the removal of irritating toxic compounds in the gas phase.
Approximately 25% of the world population are smokers.
Sensi Filter technology may indeed offer the tobacco industry a common sense solution, without forcing lifestyle changes on those who don't want to or who are unable to quit smoking.
Market size assumptions are as follows:
1.2 billion smokers (Source: World Health Organization - WHO/38-30 May 2000) multiplied by an assumed average 1 pack per day multiplied by 365 days per year equates to a market size of 438,000,000,000 (billion) packs per year.
Upon further successful product validation, Immulabs intends to pursue cigarette manufacturers to license 'Sensi FilterTM' for inclusion in 100% of their products including Philip Morris (MO:NYSE), RJ Reynolds (RJR:NYSE), Rothmans (ROC.TSE), British-American Tobacco (BTI:AMEX), Star Tobacco (STSI:Nasdaq).
NTAssayTM
The impact of the NTAssayTM on Host Defense System research could be considerable, since the function of the latter is to protect the host against infectious diseases, inflammatory diseases and cancer.
The ability to obtain these white cells in a viable state and then test the impact of toxic substances on them in a controlled environment in vivo (inside the body) and in vitro (outside the body) is of great value.
Potential Applications of NTAssayTM
Immulabs plans to make the NTAssayTM available to researchers in the medical, dental, veterinary medicine and pharmaceutical fields.
Both humans and mammals at times face the same dangers from pathogens. In addition to approximately one trillion dollars spent every year for human medical and dental care in the USA, billions more are spent on veterinary care for animals including livestock and pets. The recent outbreak of Mad Cow disease in Great Britain is an example of the danger that pathogens pose to cattle and, indirectly, to humans, evidencing how critically the human medical and the veterinary fields are entwined.
To see the complete story regarding these exciting new technologies, visit our website today at: immulabs.com.
Background:
Immulabs' strategy is to acquire significantly developed Biotechnology / Biomedical companies or technologies nearing market readiness that provide unique and valuable benefits to the immune system. Immulabs intends to provide an infrastructure for global commercialization of such technologies.
Nasdaq Index firms in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services include Amgen Inc. (NASDAQ:AMGN), Biogen, Inc. (NASDAQ:BGEN), Genzyme Corporation (NASDAQ:GENZ), Human Genome Sciences, Inc. ( NASDAQ:HGSI), Immunex Corporation (NASDAQ:IMNX) and Medimmune Inc. (NASDAQ:MEDI).
Immulabs also announced today that Mr. Bruce Deildal replaced Mr. Ben Traub as the Company's new President and CEO and Director. Mr. Ben Traub will continue to assist Immulabs from his position as President of Cyclone Financing Group Inc. (CFGi). Immulabs retained CFGi last June to assist and advise in the negotiations and acquisitions of immune-focused biotechnology opportunities. CFGi will continue in its role in the implementing of Immulabs' corporate vision, advising on the acquisition of high-potential business opportunities to match that vision, recruiting a senior management team to build the business into a global presence, and laying the foundation for a listing on a major exchange.
Legal Notice Regarding the Statements in this Release:
Certain information included in this release contain statements that are forward looking, such as statements related to the future anticipated direction of the industry, plans for future expansion, the ability to acquire the technologies described and the Company which developed these technologies, expected independent validation of the technologies or product(s), success or potential of the technologies described and acceptance of such technologies by industry and the market, various business development activities, planned capital expenditures, future funding resources, anticipated sales growth and potential contracts and subsequent return for investors. These are all forward looking statements, and are subject to a number of known and unknown risks and uncertainties that could cause actual operation or results to differ materially from those that are anticipated.
While Immulabs' stated mission is to develop revolutionary technology into highly focused and successful businesses, it is unrealistic and premature to speculate on Immulabs' future revenue at this time, except as to the difficulties involved.
Immulabs entire success and each step required to achieve such success depends on its ability to raise significant further financing on an ongoing basis and there is no guarantee it will be able to do so. The company is still in the development stage and has no revenues. Additionally, funds may be raised through the issuance of equity shares and such securities might have rights, preferences or privileges senior to its common stock and will likely result in dilution to existing shareholders.
Readers are cautioned that Immulabs does not own the technology herein described, nor does it own the originator of such technology, Quest Research Group Inc. At this point, Immulabs only has rights assigned under an option agreement to acquire such technology, which agreement may or may not be completed by the parties, in multiple stages, none of which have yet been exercised or completed. Each such stage will require considerable further financing and there is no guarantee Immulabs will be able to secure such financing, or that it can secure it on terms favorable to Immulabs. Investors are cautioned that this or any other agreement entered into by Immulabs may also be subject to future legal claims or challenges, or attempts at repudiation.
Any and all claims in this release of any nature, particularly scientific claims, including those with respect to Sensi Filter'sTM or NT Assay'sTM capabilities such as the ability to monitor, gauge, and reduce damage to white blood cells as described herein, and any implications that it may thereby lead to less hazardous cigarette smoke or other benefits, require further research and independent validation, and investors are cautioned to await such additional research and validation before relying upon the claims herein. There can be no guarantee as to the results such further scrutiny will provide.
Many additional important factors may affect the Company's likelihood of future success including; difficulties in successfully raising capital (given the Company's lack of operating history, lack of profitable operations presently and for the foreseeable future and lack of a market for the Company's securities), in developing and commercializing its products (including the ability to overcome technical hurdles that may arise), in meeting applicable existing or new regulatory standards, in receiving required regulatory approvals, in obtaining necessary patents and licenses, in defending against third party infringement of patents and licenses, in protecting itself from costly, unforeseen legal disputes, in producing NTAssayTM and Sensi FilterTM products in commercial quantities at reasonable costs, in competing successfully against other products and in marketing products successfully and in successfully addressing the concerns and/ or obtaining the support of the anti-tobacco lobbies in various countries. There can be no assurance that the Company will be successful in its efforts to develop and commercialize new products.
CONTACT:
Immulabs Corporation
Mark Sommer,
888/763-6547 or 604-646-5516
www.immulabs.com |
